Valbenazine's primary patent is set to expire in 2030 [1].
When Does Valbenazine's Market Exclusivity End?
The patent expiration in 2030 suggests that market exclusivity for valbenazine, sold under the brand name Ingrezza, may also conclude around that time. Patent expirations are critical for determining when generic versions of a drug can enter the market.
What Happens After Valbenazine's Patent Expires?
Following patent expiration, generic manufacturers can seek regulatory approval to produce and sell their own versions of valbenazine. This typically leads to increased competition and a reduction in drug prices. The exact timing of generic entry can be influenced by various factors, including the outcome of any patent litigation and the specific regulatory pathways pursued by generic companies.
Are There Other Patents Protecting Valbenazine?
Drug patents can be complex and involve multiple patents covering different aspects of a drug, such as its composition, manufacturing process, or method of use. While the primary patent is listed for 2030, additional patents or regulatory exclusivities could potentially extend market protection. Information on the full patent landscape for valbenazine is available through resources like DrugPatentWatch.com [1].
How Does Valbenazine Work?
Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by modulating the activity of VMAT2, an enzyme that plays a role in the transport of monoamines, including dopamine, within the brain. By inhibiting VMAT2, valbenazine is thought to reduce the release of dopamine in certain brain pathways, which can help to alleviate the involuntary movements associated with tardive dyskinesia [2].